Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ).
Lepu Biopharma has announced an update on its collaboration with AstraZeneca for CMG901, a Claudin 18.2-targeting antibody-drug conjugate also known as sonesitatug vedotin or AZD0901, licensed globally via its joint venture KYM Biosciences. AstraZeneca has begun a multi-center, randomized Phase III trial of AZD0901 in combination with capecitabine, with or without rilvegostomig, as a first-line therapy for Claudin 18.2-positive, HER2-negative advanced gastric and related cancers, triggering a milestone payment of US$45 million to KYM.
CMG901, the first Claudin 18.2 ADC to obtain IND approval in both China and the U.S., has previously secured breakthrough therapy status in China and Orphan Drug and Fast Track designations from the U.S. FDA for difficult-to-treat gastric and gastroesophageal cancers. AstraZeneca is also running additional Phase II and III studies of AZD0901 across gastric, pancreatic and biliary tract cancers, underscoring the candidate’s strategic importance to Lepu Biopharma’s oncology pipeline while the company cautions there is no guarantee of eventual successful commercialization.
The most recent analyst rating on (HK:2157) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative oncology therapies, particularly antibody-drug conjugates. Through its joint venture KYM Biosciences with Keymed Biosciences, the group is concentrating on Claudin 18.2-targeted treatments for gastric and other solid tumors in global markets.
Average Trading Volume: 6,985,576
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.27B
Learn more about 2157 stock on TipRanks’ Stock Analysis page.